肺癌中ERCC1的真相。 - Suppr

Suppr

超能文献

Truth about ERCC1 in lung cancer.

作者信息

Tan Daniel S-W, Ng Quan-Sing, Tan Iain B-H, Lim Soon-Thye, Lim Wan-Teck

出版信息

J Clin Oncol. 2010 Apr 1;28(10):e162; author reply e164. doi: 10.1200/JCO.2009.26.6270. Epub 2010 Feb 16.

DOI:10.1200/JCO.2009.26.6270

PMID:20159806

Abstract

摘要

相似文献

Truth about ERCC1 in lung cancer.

J Clin Oncol. 2010 Apr 1;28(10):e162; author reply e164. doi: 10.1200/JCO.2009.26.6270. Epub 2010 Feb 16.

[Histoculture drug response assay guided adjuvant chemotherapy in patients with ERCC1-positive non-small cell lung cancer].

Gan To Kagaku Ryoho. 2009 Apr;36(4):611-4.

[ERCC1 and lung cancer].

Rev Mal Respir. 2010 Apr;27(4):387-94. doi: 10.1016/j.rmr.2010.03.003. Epub 2010 Mar 25.

Different impact of excision repair cross-complementing group 1 on survival.

J Clin Oncol. 2010 Apr 1;28(10):e163; author reply e164. doi: 10.1200/JCO.2009.26.6619. Epub 2010 Feb 16.

Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.

Lung Cancer. 2009 Jun;64(3):326-33. doi: 10.1016/j.lungcan.2008.09.002. Epub 2008 Nov 1.

ERCC1-specific immunostaining in non-small-cell lung cancer.

N Engl J Med. 2007 Oct 11;357(15):1559-61. doi: 10.1056/NEJMc072007.

DNA repair by ERCC1 in non-small-cell lung cancer.

N Engl J Med. 2006 Dec 14;355(24):2591; author reply 2591. doi: 10.1056/NEJMc062750.

Expression of excision repair cross-complementation group 1 and class III beta-tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer.

Lung Cancer. 2008 Oct;62(1):105-12. doi: 10.1016/j.lungcan.2008.02.021. Epub 2008 Apr 18.

ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer.

Curr Opin Pulm Med. 2007 Jul;13(4):284-9. doi: 10.1097/MCP.0b013e32816b5c63.

DNA repair by ERCC1 in non-small-cell lung cancer.

N Engl J Med. 2006 Dec 14;355(24):2590; author reply 2591.

引用本文的文献

Commercial laboratory testing of excision repair cross-complementation group 1 expression in non-small cell lung cancer.

Oncologist. 2014 May;19(5):459-65. doi: 10.1634/theoncologist.2013-0311. Epub 2014 Apr 4.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Truth about ERCC1 in lung cancer.

J Clin Oncol. 2010 Apr 1;28(10):e162; author reply e164. doi: 10.1200/JCO.2009.26.6270. Epub 2010 Feb 16.

[Histoculture drug response assay guided adjuvant chemotherapy in patients with ERCC1-positive non-small cell lung cancer].

Gan To Kagaku Ryoho. 2009 Apr;36(4):611-4.

[ERCC1 and lung cancer].

Rev Mal Respir. 2010 Apr;27(4):387-94. doi: 10.1016/j.rmr.2010.03.003. Epub 2010 Mar 25.

Different impact of excision repair cross-complementing group 1 on survival.

J Clin Oncol. 2010 Apr 1;28(10):e163; author reply e164. doi: 10.1200/JCO.2009.26.6619. Epub 2010 Feb 16.

Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.

Lung Cancer. 2009 Jun;64(3):326-33. doi: 10.1016/j.lungcan.2008.09.002. Epub 2008 Nov 1.

ERCC1-specific immunostaining in non-small-cell lung cancer.

N Engl J Med. 2007 Oct 11;357(15):1559-61. doi: 10.1056/NEJMc072007.

DNA repair by ERCC1 in non-small-cell lung cancer.

N Engl J Med. 2006 Dec 14;355(24):2591; author reply 2591. doi: 10.1056/NEJMc062750.

Expression of excision repair cross-complementation group 1 and class III beta-tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer.

Lung Cancer. 2008 Oct;62(1):105-12. doi: 10.1016/j.lungcan.2008.02.021. Epub 2008 Apr 18.

ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer.

Curr Opin Pulm Med. 2007 Jul;13(4):284-9. doi: 10.1097/MCP.0b013e32816b5c63.

DNA repair by ERCC1 in non-small-cell lung cancer.

N Engl J Med. 2006 Dec 14;355(24):2590; author reply 2591.

引用本文的文献

Commercial laboratory testing of excision repair cross-complementation group 1 expression in non-small cell lung cancer.

Oncologist. 2014 May;19(5):459-65. doi: 10.1634/theoncologist.2013-0311. Epub 2014 Apr 4.